Barbara Ryan
Barbara Ryan
Barbara Ryan Colemanis a fictional character from the American CBS soap opera As the World Turns. In the early 1970s, Barbara was played by a succession of actresses, but the actress most associated with the role is Colleen Zenk, who played her since September 1, 1978. Better known as simply Barbara Ryan she is portrayed as a heroine who experienced many tragedies, mostly at the hands of her controlling ex-husband, the villainous James Stenbeck...
company earnings improve merger pursuing
The only way this company can improve their earnings is through pursuing a merger or by being acquired. It's not very innovative, but it's what they're going to have to do.
clear company growth vehicle view
The only company which is a clear growth vehicle in our view is Schering-Plough.
altogether cash certainty clearly company disregard generic given greater industry litigation settle translate tremendous unlikely
Pfizer clearly is a company with tremendous disregard for the generic drug industry and is not given to settling. But it is not altogether unlikely that Pfizer could settle its litigation. If Pfizer could translate some of its cash hoards into greater certainty on this litigation ... I think they would do that.
company heads left management problems roll vulnerable zero
We're left with a company with a litany of problems and a management that has zero credibility. I think some heads will roll and they will be very vulnerable to take-out.
aided company deliver despite earnings faced pressures top
Despite the pressures that Pfizer has faced and will face on the top line, the company will be able to deliver on their earnings target, in part aided by introduction of their new drugs.
benefits company flow focus improving investors late likely product
Investors and company managements will likely focus on the benefits of restructuring and the improving new product flow for late 2006.
company gone radical
The company has gone through a radical transformation,
products quite spending terms today visible
There is a 10-year lag in R&D spending, ... The spending that they're doing today isn't going to be visible in terms of products for quite some time.
believe strategic
We believe Merck has put in place an aggressive, but achievable strategic plan.
based cost earnings expect recovery year
Bristol-Myers earnings will be down this year but then we expect to see a recovery based on the introduction of new drugs and cost cuts.
companies deliver fairly results slightly
Expectations are fairly low, and these companies will deliver results that are in-line, or slightly better than expectations.
behind cases modest positive
modest positive for the stock, modest because they have 6,000 cases behind this one.
appears economics far merger neutral quite revenue short somewhat stock trend
So far the integration appears to be going well. The economics of the merger are going to be quite strong. We're somewhat disappointed in the near-term revenue trend and are neutral on the stock in the short run.
billion build dollar few sales takes
New drugs are not going to build billion dollar sales in a few weeks. It takes years to do that.